Cohance to invest $10 million to expand cGMP bioconjugation capabilities in US

NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline

LAXAI Life Sciences appoints Sripathy Venkatraman as CEO

Dr. Venkatraman brings over 25 years of experience in small molecule and Biologics drug development, manufacturing, and advancing strategic growth initiatives

Aurobindo Pharma Q1 FY26 PAT slips 10% YoY to Rs. 824 Cr

Aurobindo Pharma’s US formulations revenue slipped 1.9% on a year-on-year basis to Rs. 3,488 crore

Cupid Q1 FY26 PAT jumps 82% at Rs. 15 Cr

Cupid reported total income of Rs. 64.75 crore in Q1 FY26 as compared to Rs. 44.03 crore in Q1 Fy25

Metropolis Healthcare reports Q1 FY26 PAT higher by 19% at Rs. 45 Cr

Indegene posts Q1 net profit higher by 33% YoY to Rs. 116.4 Cr

The operating profit (EBITDA) rose 20.7% to Rs. 156.4 crore

Aurobindo to acquire Lannett Company for Rs. 2,185 Cr

The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities

Trixeo Aerosphere receives positive EU CHMP opinion as first inhaled medicine with near-zero GWP

Trixeo is the first pMDI medicine in AstraZeneca’s portfolio to use the near-zero GWP propellant

Vijaya Diagnostic reports Q1 FY26 consolidated PAT at Rs. 38.33 Cr

The company would be commissioning 3 hubs in Q2 FY26 across our Core Geography and West Bengal

Merck unveils $3 billion cost cutting plan

The savings will be fully reinvested to support new product launches and its pipeline across multiple therapeutic areas